| # | Title | Journal | Year | Citations |
|---|
| 1 | Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) | Autophagy | 2016 | 4,701 |
| 2 | Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial | Lancet, The | 2016 | 3,077 |
| 3 | Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines | Blood | 2008 | 2,887 |
| 4 | Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial | Lancet, The | 2017 | 1,728 |
| 5 | Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma | Nature Medicine | 2018 | 900 |
| 6 | Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial | Lancet, The | 2019 | 778 |
| 7 | Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib | JAMA Oncology | 2020 | 746 |
| 8 | Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes | Clinical Cancer Research | 2016 | 705 |
| 9 | Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1) | Cancer Discovery | 2017 | 647 |
| 10 | Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial | Breast Cancer Research and Treatment | 2001 | 629 |
| 11 | Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer | New England Journal of Medicine | 2021 | 601 |
| 12 | Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update | Journal of Clinical Oncology | 2021 | 580 |
| 13 | Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial | Lancet, The | 2016 | 529 |
| 14 | Toxicities of Immunotherapy for the Practitioner | Journal of Clinical Oncology | 2015 | 521 |
| 15 | Effects of Mammography Screening Under Different Screening Schedules: Model Estimates of Potential Benefits and Harms | Annals of Internal Medicine | 2009 | 509 |
| 16 | Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial | Lancet Oncology, The | 2020 | 466 |
| 17 | First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin | Annals of Oncology | 2002 | 458 |
| 18 | 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO | Nucleic Acids Research | 1991 | 389 |
| 19 | A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma | Nature Medicine | 2009 | 382 |
| 20 | Understanding breast cancer risk - where do we stand in 2005? | Journal of Cellular and Molecular Medicine | 2005 | 369 |
| 21 | Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials | British Journal of Cancer | 2004 | 368 |
| 22 | A Novel Human Prostate-Specific, Androgen-Regulated Homeobox Gene (NKX3.1) That Maps to 8p21, a Region Frequently Deleted in Prostate Cancer | Genomics | 1997 | 331 |
| 23 | Thrombocytopenia following Pfizer and Moderna SARS‐CoV‐2 vaccination | American Journal of Hematology | 2021 | 331 |
| 24 | Discovery of Small-Molecule Inhibitors of Bcl-2 through Structure-Based Computer Screening | Journal of Medicinal Chemistry | 2001 | 325 |
| 25 | Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women | Cancer | 2003 | 305 |
| 26 | Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial | Lancet Oncology, The | 2018 | 305 |
| 27 | Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma | Cancer Treatment Reviews | 2018 | 276 |
| 28 | Beta-catenin mutations in human prostate cancer | Cancer Research | 1998 | 274 |
| 29 | Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting | Blood Reviews | 2020 | 267 |
| 30 | Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer | Blood Reviews | 2022 | 267 |
| 31 | Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade | Cancer Cell | 2020 | 262 |
| 32 | TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases | Journal of Clinical Oncology | 2019 | 251 |
| 33 | Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC | Cancer Immunology Research | 2016 | 247 |
| 34 | Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial | Lancet Oncology, The | 2015 | 240 |
| 35 | Bendamustine: Rebirth of an Old Drug | Journal of Clinical Oncology | 2009 | 237 |
| 36 | Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma | Cancer Immunology Research | 2015 | 237 |
| 37 | The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma | Cancer | 2016 | 236 |
| 38 | Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial | Lancet Oncology, The | 2022 | 236 |
| 39 | Novel, Rapid, and Inexpensive Cell-Based Quantification of Antimalarial Drug Efficacy | Antimicrobial Agents and Chemotherapy | 2004 | 234 |
| 40 | Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. | Journal of Clinical Oncology | 1997 | 223 |
| 41 | Trimester-Specific Changes in Maternal Thyroid Hormone, Thyrotropin, and Thyroglobulin Concentrations During Gestation: Trends and Associations Across Trimesters in Iodine Sufficiency | Thyroid | 2004 | 211 |
| 42 | Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation | Addiction | 2010 | 207 |
| 43 | Hyperactivation of MAPK Induces Loss of ERα Expression in Breast Cancer Cells | Molecular Endocrinology | 2001 | 206 |
| 44 | Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review | JNCI Cancer Spectrum | 2018 | 199 |
| 45 | Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors | Cancer | 2014 | 195 |
| 46 | Ginkgo biloba extracts and cancer: a research area in its infancy | Fundamental and Clinical Pharmacology | 2003 | 194 |
| 47 | Modulation of Transcription Factor Sp1 by cAMP-dependent Protein Kinase | Journal of Biological Chemistry | 1997 | 191 |
| 48 | Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer | Clinical Cancer Research | 2018 | 190 |
| 49 | Ethnic differences in knowledge and attitudes about BRCA1 testing in women at increased risk | Patient Education and Counseling | 1997 | 186 |
| 50 | Impact of Lung Cancer Screening Results on Smoking Cessation | Journal of the National Cancer Institute | 2014 | 183 |
